entertainment -WSS

entertainment

author：fashion 2025-09-30 17:27:35 - browse：97443

Christopher Boerner -- biotech JPM coverage from STAT — Bristol CEO Christopher Boerner Business Wire via AP

SAN FRANCISCO — Christopher Boerner has been the CEO of Bristol Myers Squibb for just two months. But in trying to sell the company to investors on Monday at the annual J.P. Morgan Healthcare Conference, he pointed to the company’s 150-year history.

He spoke of the “next chapter” for BMS, which saw its stock fall 27% last year, and said that the company would be going through a “period of renewal.” Basically, the tide comes in, but it also goes out. Patents on big-selling medicines expire, but new medicines will come to take their place.

Investors may not be able to view those changes with equanimity. Sales of Bristol’s top sellers will decline significantly or vanish as generic or biosimilar medicines emerge. That includes Eliquis, the blood thinner for stroke prevention that will be one of the first medications subject to price negotiation under the Inflation Reduction Act; Revlimid, the best-selling multiple myeloma medicine that Bristol acquired when it bought Celgene for $74 billion in 2019; and Opdivo, Bristol’s pioneering cancer immunotherapy, which is an $8 billion seller.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Zyn nicotine pouches become unlikely player in latest culture war

WSS

FTC sues over Novant Health acquisition of two N.C. hospitals

Mindstrong's demise and the future of mental health care

10 reasons why health care startups fail

FDA seeks to regulate lab

STAT Virtual Event: How to Increase Diversity in Clinical Trials

Data show record exodus of life scientists from academia

entertainment

entertainment

focus

DIEP, the 'gold standard' of breast reconstruction, is under threat

Merck, Johnson & Johnson CEOs will testify on high drug prices

Hepatitis C has a cure — but many Americans still lack access to it

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

New air purifier tech could be key to improving indoor air quality

Did you have Obamacare on your GOP debate bingo card?

Psychedelics group wrestles with new pharma identity

Wegovy leads to weight loss. Can it treat depression, too?

Tori Bowie and the unacceptable rates of Black maternal death

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

focus

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

Boston competes with Raleigh

New clues to why women have higher risk of autoimmune disorders

Would Medicare drug price negotiations stall in a shutdown?

Merck CEO won’t testify in Senate, citing no expertise in drug prices

How one patient went off dialysis — and others can too

hotspot

focus

focus

Wikipedia